EX-99.2 7 tm214487d1_ex99-2.htm EXHIBIT 99.2 Exhibit
Takhzyro (lanadelumab-flyo) for treatment of hereditary angioedema
Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema - Anderson - 2022 - Clinical and Translational Allergy - Wiley Online Library
These highlights do not include all the information needed to use TAKHZYRO® safely and effectively. See full prescribing information for TAKHZYRO®. TAKHZYRO® (lanadelumab-flyo) injection, for subcutaneous useInitial U.S. Approval: 2018
An open‐label study to evaluate the long‐term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension - Riedl - 2017 - Clinical and
Frontiers | Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency | Immunology
Mechanism of action has an impact on antibody dose escalations. The... | Download Scientific Diagram
TAKHZYRO® (lanadelumab‐flyo) Mechanism of Action
Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency | Immunotherapy
Site of action of current and under research therapies for HAE treatment. | Download Scientific Diagram
Hereditary Angioedema | NEJM
Lanadelumab Injection Treatment For The Prevention Of Hereditary Angio | DDDT
Takhzyro - FDA prescribing information, side effects and uses
Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema | Immunotherapy
A Primer on Hereditary Angioedema — tl;dr pharmacy
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema - The Journal of Allergy and Clinical Immunology: In Practice
Lanadelumab
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients | Business Wire
NDC 47783-644 Takhzyro Lanadelumab-flyo
TAKHZYRO® (lanadelumab‐flyo) Mechanism of Action
TAKHZYRO™ (lanadelumab injection) Now Approved
Takhzyro (lanadelumab-flyo) for treatment of hereditary angioedema
Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2 | SpringerLink
